CRL · NYSE · STOCK
Charles River Laboratories (CRL) Stock Analysis
$286.67
52W $144.26 – $288.02
56/100
$13.49B
-57.9
1.38
Is CRL Bullish or Bearish?
Bullish.
Innellis AI committee rates Charles River Laboratories (CRL) Buy with a composite score of 56/100
, based on 6 analysts with 50% agreement.
Last updated August 17, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +18.73 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -1.27 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 39.4% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- ROE of only -7.7% -- cheap may mean cheap for a reason — Value
- Revenue declining -0.7% YoY -- this is not a growth story right now — Growth
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 39.4% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 17, 2026
Overall Committee Score
56/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 74%
of 192 Healthcare peers
Value Analyst
neutral
42
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -7.7% -- cheap may mean cheap for a reason
Growth Analyst
bullish
60
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
− Revenue declining -0.7% YoY -- this is not a growth story right now
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 78 is in overbought territory
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 39.4% signals elevated volatility
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2963.04)
Investment Thesis Evolution
Committee score moved marginally from 56.3 to 56.3.
- Recommendation changed from Watch to Buy.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Portfolio Manager: +1 bearish signal(s).
Comparing 2026-08-16 to 2026-08-17 (1 day apart).
Technical Analysis
RSI (14)
77.7
Overbought
MACD Histogram
3.299
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$259.98
Resistance
$302.63
Bollinger %B
0.83
Inside Bands
Price vs Moving Averages
EMA 9
$270.13
Above
EMA 21
$253.03
Above
EMA 50
$229.40
Above
EMA 200
$195.30
Above
Fundamental Analysis
Valuation
83
Growth
82
Profitability
8
Financial Health
59
Cash Flow
70
Valuation
P/E Ratio
-57.9×
P/B Ratio
4.78×
PEG Ratio
0.60
Dividend Yield
0.00%
52W High
$288.02
52W Low
$144.26
Quality & Growth
ROE
-456.1%
ROA
-202.3%
Gross Margin
3224.2%
Operating Margin
1234.8%
Revenue Growth YoY
—
Debt / Equity
1.07
AI Fundamental Assessment
P/E ratio of -57.9 (inexpensive relative to a 15-40x range); Price-to-book of 4.8x; PEG ratio of 0.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -4.6%; Return on assets of -2.0%; Net margin of -6.0%; Gross margin of 32.2%; Current ratio of 1.35 (tight short-term liquidity); Debt-to-equity of 1.07; Free cash flow per share is positive (7.64); Most recent quarter beat estimates by 9.2%; 5 consecutive earnings beats; EPS growth accelerating (-13.8% -> +46.6% QoQ); Average YoY EPS growth of -3.2%; Analyst estimates rising over recent quarters
Get the Full CRL Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →